For U.S. Residents Only

Patient assistance is offered through CABLIVI Patient Solutions

Going home from the hospital with a new medicine can be overwhelming. CABLIVI Patient Solutions is here with patient assistance to help you during this transition.

patients-img

Sanofi reserves the right to modify or terminate these programs at any time without notice.

icon-img

Specialty pharmacy services

Getting started

If your doctor prescribes CABLIVI through Biologics by McKesson specialty pharmacy:

  • A dedicated Case Manager will coordinate with your dispensing specialty pharmacy to help with the transition to receive your CABLIVI therapy at home.
  • Dispensing pharmacists are available 24 hours a day, 7 days a week
Refills

If your doctor decides you need a refill, you'll receive a phone call from the specialty pharmacy to arrange your delivery of CABLIVI according to your doctor's prescription.

icon-img

Financial assistance

  • Support is available to cover the cost of CABLIVI co-pay or co-insurance for qualified, commercially insured patients up to the program maximum
  • CABLIVI will be provided at no cost to eligible, underinsured, or uninsured patients
icon-img

Supplemental training

Clinical educatorsยง are available to provide the following in your home at no cost to you:
  • Additional training on how to administer CABLIVI by yourself
  • Answers to questions about CABLIVI
  • Support in setting up a plan for administering therapy (e.g., deciding a time to take CABLIVI each day)

Therapeutic Education Managers (TEMs) are here for ongoing education with understanding and living with aTTP/iTTP

A team of educators experienced in rare blood disorders is committed to educating people living with aTTP/iTTP, their families, and care partners. These Therapeutic Education Managers, or TEMs for short, can speak with you about topics such as what aTTP/iTTP is, questions to ask your healthcare provider, and having conversations with your healthcare team. Individual phone calls and written information are available from TEMs to connect you to helpful resources and information. Contact CABLIVI Patient Solutions (1-855-724-7222) to learn more.

TEMs are paid to provide educational services on behalf of Sanofi. They don't provide medical advice. You should always talk to your doctor about any healthcare needs.

*You must have been prescribed CABLIVI to receive a welcome kit and enroll in the program.
Not valid for CABLIVI prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DoD, Tricare, or similar federal or state programs including any state pharmaceutical assistance programs. Not valid where prohibited by law. Savings may vary depending on the patient's out-of-pocket costs. Upon registration, the patient will receive all program details.
Approval is not guaranteed.
§CABLIVI clinical educators are paid to provide educational services on behalf of Sanofi. They don't provide medical advice. You should always talk to your doctor about any healthcare needs.
aTTP is also known as iTTP. The terms can be used interchangeably.
pdf-view

CABLIVI Patient Solutions

Learn more about the support offered through CABLIVI Patient Solutions.

Download
pdf-view

CABLIVI Patient Solutions Enrollment Form

Enroll in CABLIVI Patient Solutions for specialty pharmacy services, administration training, financial assistance, and more.

Download

CABLIVI can help make a difference

See how CABLIVI may help you
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Who should not take CABLIVI?

Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?
Add
IMPORTANT SAFETY INFORMATION AND INDICATIONS
What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Who should not take CABLIVI?

Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.

Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.

You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.

CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.

The most common side effects include nosebleed, headache and bleeding gums.

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

Please see full Prescribing Information
Instructions for Use
Sharps Medical Waste Disposal (PDF)

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

aTTP=acquired thrombotic thrombocytopenic purpura; iTTP=immune-mediated thrombotic thrombocytopenic purpura; TTP=thrombotic thrombocytopenic purpura.